๐ฌIn plain words
What the trial is, and whether it could suit you
This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI) โฅ23.0 kilograms per meter squared (kg/m\^2).
Sign in to get the eligibility rules as simple questions to take to your doctor.
๐ Eligibility rules (as published)
Inclusion Criteria:
* No evidence of active or chronic disease as determined by detailed medical and surgical history and the results of a physical examination, vital signs, 12 lead electrocardiogram (ECG), or clinical laboratory tests
* BMI โฅ23 kg/m\^2 at screening
* Agreement to adhere to the contraception requirements
Exclusion Criteria:
* History of acute or chronic pancreatitis
* History of clinically significant gallbladder disease in the opinion of the investigator
* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder
* History or presence of an abnormal ECG that is deemed clinically significant in the opinion of the investigator
* Clinically significant abnormalities (as judged by the investigator) in laboratory test results
* History or presence of clinically significant cardiovascular disease, renal disease, hepatic disease, gastrointestinal disease, hematological disease, immunological disease, neurological disease, endocrine disease, metabolic disease, pulmonary disease, or history of any of these diseases with renal, hepatic, or cardiopulmonary dysfunction
Peking University First Hospital
Beijing, China
๐ค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ always decide together with your own doctor.